Geng Qingwei, Xu Junzhu
Department of Dermatology, Hangzhou Third People's Hospital, Zhejiang, China.
J Dermatolog Treat. 2025 Dec;36(1):2556487. doi: 10.1080/09546634.2025.2556487. Epub 2025 Sep 4.
Sarcoidosis is a chronic, multisystem granulomatous disorder characterized histologically by non-caseating granulomas. Despite the availability of various therapeutic options, long-term disease control remains a significant clinical challenge.
We report the case of a 55-year-old female diagnosed with sarcoidosis. Skin and lymph node biopsies revealed non-caseating granulomatous inflammation, and chest CT indicated pulmonary involvement. Infectious causes of granulomatous disease, including Mycobacterium tuberculosis, non-tuberculous mycobacteria, and fungal infections, were excluded through com-prehensive testing. The patient initially received conventional systemic corticosteroid therapy but developed treatment-related complications. Due to the need for sustained disease control, an alternative regimen combining low-dose corticosteroids with the selective JAK1 inhibitor abrocitinib was initiated.
The patient showed significant clinical improvement following the combination therapy, with no observed treatment-related adverse events.
This case suggests that low-dose corticosteroids combined with a JAK1 inhibitor such as abrocitinib may represent a treatment option for patients with sarcoidosis.
结节病是一种慢性多系统肉芽肿性疾病，组织学特征为非干酪样肉芽肿。尽管有多种治疗选择，但长期疾病控制仍然是一项重大的临床挑战。
我们报告了一例55岁女性被诊断为结节病的病例。皮肤和淋巴结活检显示非干酪样肉芽肿性炎症，胸部CT提示肺部受累。通过全面检测排除了肉芽肿性疾病的感染原因，包括结核分枝杆菌、非结核分枝杆菌和真菌感染。患者最初接受了传统的全身糖皮质激素治疗，但出现了治疗相关并发症。由于需要持续控制疾病，启动了一种将低剂量糖皮质激素与选择性JAK1抑制剂阿布昔替尼联合使用的替代方案。
联合治疗后患者临床症状显著改善，未观察到治疗相关不良事件。
该病例表明，低剂量糖皮质激素联合JAK1抑制剂如阿布昔替尼可能是结节病患者的一种治疗选择。
